The purchase orders support the planned expansion of commercial activities, including increased market penetration, accelerated system placements and continued growth in LITT procedures and disposable procedure kits. The parties have also agreed on the product delivery planning as part of the accelerated growth initiative.

"We are pleased to now see the first tangible commercial outcome from the agreement reached with our strategic partner on the accelerated growth plan for the Prism business. These purchase orders, together with the agreed delivery schedule, further support our expectations of increased commercial activity and revenue growth going forward. At the same time, CLS remains fully committed to executing on its part of the agreement through continued investments in product scalability, product development, regulatory initiatives and operational readiness," commented Dan J. Mogren, CEO of CLS.

As previously communicated, the accelerated growth plan includes coordinated activities related to market expansion, product development, regulatory initiatives and long-term strategic collaboration.

For more Information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-post: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se